Upregulation of SOCS-1 by Nutlin-3 in acute myeloid leukemia cells but not in primary normal cells

by Veronica Tisato, Alessia Norcio, Claudio Celeghini, Daniela Milani, Arianna Gonelli, Paola Secchiero
Published 2014-01-01

Planejamento, síntese e avaliação farmacológica de novos candidatos a protótipos de fármacos antitumoral análogos ao composto LQFM 030

by Carvalho, Flávio Silva de
Published 2017

Sénescence cellulaire et nouvelles approches thérapeutiques de l'hypertension artérielle pulmonaire

by Mouraret, Nathalie
Published 2013

Avaliação do potencial antagonista da interação p53-MDM2 do composto LQFM030 frente à linhagem tumoral K562

by Ribeiro, Higor de Oliveira
Published 2018

Nutlin3a Contributes to the Cytoplasmic Retention of Androgen Receptor

by Gulseren Ozduman, Bilge Debelec Butuner, Kemal Sami Korkmaz
Published 2018-12-01

Inhibition of Transglutaminase 2 but Not of MDM2 Has a Significant Therapeutic Effect on Renal Cell Carcinoma

by Joon Hee Kang, Seon-Hyeong Lee, Jae-Seon Lee, Su-Jin Oh, Ji Sun Ha, Hyun-Jung Choi, Soo-Youl Kim
Published 2020-06-01

Synergisms of genome and metabolism stabilizing antitumor therapy (GMSAT) in human breast and colon cancer cell lines: a novel approach to screen for synergism

by Jérôme Ruhnau, Jonas Parczyk, Kerstin Danker, Britta Eickholt, Andreas Klein
Published 2020-07-01

A small molecule p53 activator attenuates Fanconi anemia leukemic stem cell proliferation

by Wei Du, Xiaoli Li, Andrew F. Wilson, Qishen Pang
Published 2018-05-01

Metformin produces growth inhibitory effects in combination with nutlin-3a on malignant mesothelioma through a cross-talk between mTOR and p53 pathways

by Kengo Shimazu, Yuji Tada, Takao Morinaga, Masato Shingyoji, Ikuo Sekine, Hideaki Shimada, Kenzo Hiroshima, Takao Namiki, Koichiro Tatsumi, Masatoshi Tagawa
Published 2017-05-01

Dynamic behavior of the p53-Mdm2 core module under the action of drug Nutlin and dual delays

by Juenu Yang, Fang Yan, Haihong Liu
Published 2021-05-01

Clinical overview of MDM2/X targeted therapies

by Andrew eBurgess, Andrew eBurgess, Kee Ming Chia, Sue eHaupt, David eThomas, David eThomas, Ygal eHaupt, Elgene eLim, Elgene eLim
Published 2016-01-01

TP53 mutant cell lines selected for resistance to MDM2 inhibitors retain growth inhibition by MAPK pathway inhibitors but a reduced apoptotic response

by Chiao-En Wu, Tsin Shue Koay, Yi-Hsuan Ho, Penny Lovat, John Lunec
Published 2019-03-01

The MDM2 ligand Nutlin-3 differentially alters expression of the immune blockade receptors PD-L1 and CD276

by Ruidong Li, Pavlina Zatloukalova, Petr Muller, Maria Gil-Mir, Sachin Kote, Simon Wilkinson, Alain J. Kemp, Lenka Hernychova, Yaxin Wang, Kathryn L. Ball, Kaixiong Tao, Ted Hupp, Borivoj Vojtesek
Published 2020-08-01

P53-MDM2 PATHWAY: EVIDENCES FOR A NEW TARGETED THERAPEUTIC APPROACH IN B-ACUTE LYMPHOBLASTIC LEUKEMIA

by Stefania Trino, Luciana De Luca, Ilaria Laurenzana, Antonella Caivano, Luigi Del Vecchio, Luigi Del Vecchio, Giovanni Martinelli, Pellegrino Musto
Published 2016-12-01

MDM2-p53 Interactions in Human Hepatocellular Carcinoma: What Is the Role of Nutlins and New Therapeutic Options?

by Samy A. Azer
Published 2018-03-01

Oncogenic functions of hMDMX in <it>in vitro </it>transformation of primary human fibroblasts and embryonic retinoblasts

by van der Burg Marja JM, Wiercinska Eliza, Verlaan-de Vries Matty, Lodder Kirsten, Teunisse Amina FAS, de Lange Job, Lenos Kristiaan, Szuhai Karoly, Jochemsen Aart G
Published 2011-09-01

MDM2 Overexpression Modulates the Angiogenesis-Related Gene Expression Profile of Prostate Cancer Cells

by Thiagarajan Venkatesan, Ali Alaseem, Aiyavu Chinnaiyan, Sivanesan Dhandayuthapani, Thanigaivelan Kanagasabai, Khalid Alhazzani, Priya Dondapati, Saad Alobid, Umamaheswari Natarajan, Ruben Schwartz, Appu Rathinavelu
Published 2018-05-01

Gene Expression Profiling Identifies Important Genes Affected by R2 Compound Disrupting FAK and P53 Complex

by Vita M. Golubovskaya, Baotran Ho, Jeffrey Conroy, Song Liu, Dan Wang, William G. Cance
Published 2014-01-01

Structure based virtual screening, docking and molecular dynamic simulation studies to identify potent mdm2-p53 inhibitors: Future implications for cancer therapy

by B Vijay Raj, M V Raghavendra Rao, Yogesh Acharya
Published 2017-01-01

Computational master-regulator search reveals mTOR and PI3K pathways responsible for low sensitivity of NCI-H292 and A427 lung cancer cell lines to cytotoxic action of p53 activato...

by Ulyana Boyarskikh, Sergey Pintus, Nikita Mandrik, Daria Stelmashenko, Ilya Kiselev, Ivan Evshin, Ruslan Sharipov, Philip Stegmaier, Fedor Kolpakov, Maxim Filipenko, Alexander Kel
Published 2018-02-01